Compare APD & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APD | NTRA |
|---|---|---|
| Founded | 1940 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9B | 56.7B |
| IPO Year | 1994 | 2015 |
| Metric | APD | NTRA |
|---|---|---|
| Price | $312.42 | $315.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 22 |
| Target Price | $342.71 | ★ $408.69 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,037,300,000.00 | $210,939,000.00 |
| Revenue This Year | $4.28 | $29.65 |
| Revenue Next Year | $6.84 | $21.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $229.11 | $181.00 |
| 52 Week High | $324.00 | $437.41 |
| Indicator | APD | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 59.49 | 29.29 |
| Support Level | $289.62 | $310.50 |
| Resistance Level | N/A | $334.60 |
| Average True Range (ATR) | 6.25 | 21.23 |
| MACD | -0.26 | -12.60 |
| Stochastic Oscillator | 47.68 | 7.49 |
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the world's largest supplier of hydrogen and helium. It has a unique portfolio serving customers across industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated roughly $12 billion in revenue in fiscal 2025.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.